Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam.
Grady BP, Vanhommerig JW, Schinkel J, Weegink CJ, Bruisten SM, Lindenburg CE, Prins M
Hepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugs.
Sacks-Davis R, Daraganova G, Aitken C, Higgs P, Tracy L, Bowden S, Jenkinson R, Rolls D, Pattison P, Robins G, Grebely J, Barry A, Hellard M
Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
Hellard ME, Jenkinson R, Higgs P, Stoové MA, Sacks-Davis R, Gold J, Hickman M, Vickerman P, Martin NK
Identifying newly acquired cases of hepatitis C using surveillance: a literature review.
Sacks-Davis R, VAN Gemert C, Bergeri I, Stoove M, Hellard M
The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design.
Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, Osburn WO, Cox AL, Aitken CK, Hickman M, Hellard M, International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3)
Modelling hepatitis C transmission over a social network of injecting drug users.
Rolls DA, Daraganova G, Sacks-Davis R, Hellard M, Jenkinson R, McBryde E, Pattison PE, Robins GL